Pacira's Exparel Faces Efficacy Questions On Nerve Block Indication

US FDA advisory committee to weigh whether efficacy data support an expanded label for the local anesthetic; despite Pacira's completion of two new studies following a complete response letter, FDA continues to harbor concerns about adequacy of the data to support a broad nerve block claim.

FDAEntrance_1200x675

More from US FDA Performance Tracker

More from Regulatory Trackers